Breaking News


BSD Medical Bolsters U.S. MicroThermX® Support Team with Hiring of Shella Leahy

  BSD Medical Bolsters U.S. MicroThermX® Support Team with Hiring of Shella   Leahy  Business Wire  SALT LAKE CITY -- July 23, 2014  BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) ( today announced that it has hired Shella Leahy to provide technical, clinical, educational and field support for its MicroThermX microwave ablation system in the United States. Ms. Leahy will lead educational and training activities with customers and sales representatives throughout the United States.  “We continue to make solid inroads in the education, adoption, and use of our MicroThermX system in the United States,” said Brian Ferrand, BSD Vice President of Domestic Sales of BSD Medical. “To that end, it is imperative we make additional key hires to support our growing base of users. Shella is an exceptional addition to our team with over fifteen years of medical device experience. She practiced for many years as a Chief Technologist using equipment with patients in a hospital environment and more recently worked at a well-known, multi-billion market cap medical device company teaching medical device usage at over eighty hospitals, giving her an excellent foundation from both a customer and sales perspective. She will play an integral part in supporting our recently announced distribution agreement efforts in the West with Comed Medical Specialties.”  Ms. Leahy joins BSD from Hologic, Inc. a maker of premium diagnostic products, medical imaging systems and surgical products serving the healthcare needs of women, where she was responsible for interfacing with hospitals across California to sell and train them on new diagnostic equipment. Prior to Hologic, she spent more than a decade in hospital and clinical settings involved in all aspects of medical imaging.  About the MicroThermX ^  Microwave Ablation System  The MicroThermX Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX product line includes an innovative, high-end disposable that is used in each ablation treatment, and provides ongoing revenue streams for BSD. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX system in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.  About BSD Medical Corporation  BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s MicroThermX microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website  This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.  Contact:  Financial Profiles Tricia Ross, 310-622-8226  
Press spacebar to pause and continue. Press esc to stop.